Highlights newsletter 1
This newsletter presents you the following key sessions:
1. Video-interview with S. Verstovsek about the long-term follow-up of the COMFORT-I and COMFORT-II studies:
ruxolitinib improved overall survival with 1.5 year for patients with myelofibrosis
2. Depth of response is associated with a longer duration of response and a longer progression-free survival in the
phase III TOURMALINE-MM1 trial
3. Chronic myeloid leukemia patients with a stable molecular response may safely decrease the dose of their tyrosine
kinase inhibitor
4. Better outcomes after allogeneic hematopoietic cell transplantation with CPX-351 induction in older AML patients
5. The anti-P-selectin antibody SelG1 reduces and delays the incidence of sickle-cell related pain crises